Primary Immune Thrombocytopenic Purpura (ITP) and ITP Associated with Systemic Lupus Erythematosus: A Review of Clinical Characteristics and Treatment Modalities.
Krishna Prasad BashyalSangam ShahCalvin GhimireShravya BalmuriPradip ChaudharySandip KarkiAnuj Krishna PoudelAshbina PokharelVishal DevarkondaSamina HayatPublished in: International journal of rheumatology (2024)
Immune thrombocytopenic purpura (ITP) is an immune-mediated disorder characterized by the destruction of platelets and megakaryocytes due to autoantibodies against the platelet surface proteins. ITP without any apparent cause of thrombocytopenia is defined as primary ITP, and ITP in the setting of SLE is secondary ITP, which can be diagnosed after excluding other causes of thrombocytopenia by history, physical examination, and laboratory testing. Patients with ITP associated with SLE have higher median platelet count and less bleeding manifestations compared to the patients with primary ITP. It can be very challenging to diagnose primary ITP in SLE patients as other causes of thrombocytopenia including drug-induced thrombocytopenia, antiphospholipid syndrome, and thrombotic microangiopathic process should be ruled out. Corticosteroids are the main modality of treatment. IVIG can be used in severe cases. Splenectomy was found to be less effective in ITP associated with SLE compared to primary ITP. Control of disease activity with immunosuppressive therapy can be helpful in some cases associated with active disease flares in SLE patients.
Keyphrases
- systemic lupus erythematosus
- disease activity
- rheumatoid arthritis
- drug induced
- end stage renal disease
- rheumatoid arthritis patients
- ejection fraction
- newly diagnosed
- ankylosing spondylitis
- chronic kidney disease
- liver injury
- magnetic resonance imaging
- prognostic factors
- peritoneal dialysis
- stem cells
- patient reported outcomes
- juvenile idiopathic arthritis
- early onset
- smoking cessation
- adverse drug